Chief Financial Officer · Avalo Therapeutics, Inc. · Common Stock
Side
SELL
Value
$112K
Shares
8,457
Price
$13.23
Executed
Apr 30, 2026
Disclosed
May 1, 2026
Disclosure timeline1 days from execution to publication · legal deadline 2 business days
Apr 30 executedMay 1, 2026 disclosed
AVTX · daily
Yahoo Finance chart API
◉This trade, on the day it was made▼Disclosure●Material company filing◯Other disclosed buy◯Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Disclosed 1 business day after execution (deadline: 2)
Historical behavior+4 / 15
1 prior trade recorded in this security
Frequency & clustering+10 / 15
2 other actors traded the same direction within 14 days
Market events0 / 10
No material company filing within 60 days after the trade
Pre-arranged plan-10
Executed under a Rule 10b5-1 trading plan
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Sullivan Christopher Ryan filed this Form 4 reporting a open-market sale of AVTX on Apr 30, 2026. It became public on May 1, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Chief Financial Officer
Sullivan Christopher Ryancik:0001810417
Issuer
Avalo Therapeutics, Inc.cik:0001534120
Revision history · 0
No field has changed since this record was first ingested.
